{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-019843","form_type":"8-K","ticker":null,"cik":"0001792581","company_name":"Kiromic Biopharma, Inc.","filed_at":"2023-12-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.476945+00:00","generated_at":"2026-06-07T12:02:08.721994+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Kiromic BioPharma issues $2M 25% senior secured convertible note","bullets":["Principal $2M, interest 25% (27% on default), matures Dec 12, 2024.","Convertible at $2.50/share; beneficial ownership limitation of 9.99%.","Secured by all fixtures, equipment, and intellectual property of the company.","Senior to subordinated debt and equity; company may incur additional senior/pari/junior debt.","Issued in private placement under Section 4(a)(2) of Securities Act."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-019843","json":"https://secwatch.observer/filing/0001558370-23-019843.json","markdown":"https://secwatch.observer/filing/0001558370-23-019843.md","text":"https://secwatch.observer/filing/0001558370-23-019843.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1792581/000155837023019843/0001558370-23-019843-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1792581/000155837023019843/krbp-20231212x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T12:02:08.721994+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"809971501ccd5178bf3fcc0bf1844693295f83c0","claim":"Kiromic Biopharma, Inc. incurred senior notes of $2,000,000 with an accredited investor at 25% per annum maturing December 12, 2024.","evidence_excerpt":"2023, Kiromic BioPharma, Inc. (the “Company”) issued a 25% Senior Secured Convertible Promissory Note (the “Note”) to an accredited investor. The Note has a principal amount of $2,000,000, bears interest at a rate of 25% per annum (the “Stated Rate”) and matures on December 12, 2024 (the “Maturity Date”), on which the principal balance and accrued but unpaid","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1792581/000155837023019843/0001558370-23-019843-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"senior notes"},{"label":"Principal","value":"$2,000,000"},{"label":"Counterparty","value":"an accredited investor"},{"label":"Rate","value":"25% per annum"},{"label":"Maturity","value":"December 12, 2024"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"8de1593df83c600764fce88826395d6478f5f6c4","claim":"Kiromic Biopharma, Inc. entered into 25% Senior Secured Convertible Promissory Note with an accredited investor valued at $2,000,000 (effective 2023-12-12).","evidence_excerpt":"On December 12, 2023, Kiromic BioPharma, Inc. (the “Company”) issued a 25% Senior Secured Convertible Promissory Note (the “Note”) to an accredited investor. The Note has a principal amount of $2,000,000","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1792581/000155837023019843/0001558370-23-019843-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"an accredited investor"},{"label":"Value","value":"$2,000,000"},{"label":"Effective","value":"2023-12-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}